top of page

AMD Therapeutics LLC

Drug Repurposing and Translational Development

AMD Therapeutics develops repurposed small-molecule therapeutics by identifying new pharmacologic applications, formulations, and routes of administration for compounds with established human experience in other indications. Where appropriate, development programs may utilize the FDA 505(b)(2) regulatory pathway.

1. SCR101 — Topical therapeutic candidate for hypertrophic scar

2. AMD101 / NVX-101 — Licensed Ophthalmology Program for Neovascular AMD

AMD101 topical ophthalmic technology has been exclusively licensed to NeoVascularX, Inc., which is leading clinical development of the program as NVX-101.

These programs are being advanced to address significant unmet medical needs.

Intellectual Property
Issued patents in the United States and Japan cover aspects of the SCR101 and AMD101/NVX-101 programs. Additional patent applications relating to the AMD101/NVX-101 program have also been published.

bottom of page